Pancreatic Cancer Action Network

Research Spotlight by Dr. Anna Berkenblit

Pancreatic cancer remains one of the deadliest cancers because it is often detected at an advanced stage when treatment options are limited. PanCAN launched its 

 (EDI) to investigate whether a rise in blood sugar, in combination with other clinical signs, could serve as an early indicator of the disease.

Building on previous research, EDI aims to determine whether identifying and closely monitoring patients with newly elevated blood sugar and weight loss and utilizing the ENDPAC (Enriching New-onset Diabetes for Pancreatic Cancer) risk score could lead to earlier diagnosis and, ultimately, better outcomes. The study reached a 

 in January 2025, with full enrollment of more than 8,800 participants, and follow-up analyses are expected to provide deeper insight in the coming years.

, and involving many of the EDI investigators recently confirmed that people with glycemically-defined new-onset diabetes (GNOD) are at increased risk for pancreatic cancer. 

 important differences in risk across racial and ethnic groups.

Together, these efforts represent a bold step toward earlier detection and more equitable outcomes in pancreatic cancer. Recently I had the opportunity to interview my esteemed colleague Lynn Matrisian, PhD, MBA, Chief Science Advisor at PanCAN, who spearheaded EDI from the start. With this Q&A we had the chance to explore the motivation behind the EDI study, the significance of recent findings, and what the future may hold for early detection and screening.

Anna: What was the motivation behind launching PanCAN’s Early Detection Initiative (EDI)?

 The primary motivation was the urgent need to improve pancreatic cancer survival by diagnosing patients earlier. With the currently available treatments, shifting even a portion of diagnoses to earlier stages could significantly improve overall survival. PanCAN recognized that while advancing treatment is vital, early detection efforts must happen in parallel. The EDI was created to explore promising early indicators such as a rise in blood sugar levels, which could signal pancreatic cancer before more common symptoms appear.

Anna: How does the EDI build on previous research, and what role did the ENDPAC score play in its development?

 The EDI builds directly on research led by Dr. Suresh Chari, who discovered that a new rise in blood sugar might signal pancreatic cancer. Initially studied at the Mayo Clinic, this concept evolved through the development of the 

, which combines three clinical factors: age, change in blood sugar, and change in weight.

EDI takes this one step further by applying the ENDPAC score prospectively and offering imaging to a subset of individuals at elevated risk, helping researchers assess whether this model can meaningfully identify cancer earlier.

Anna: That’s fascinating, especially how the EDI builds on the ENDPAC score to enhance early detection. I imagine that testing such models across diverse populations is also crucial. With that in mind, what were some of the most surprising or significant findings from the recent GNOD study, particularly around racial and ethnic differences?

 In addition to confirming that a rise in blood sugar is an early warning sign of pancreatic cancer, one of the most significant findings was that the link between glycemically-defined new-onset diabetes (GNOD) and pancreatic cancer varied by race and ethnicity. While the original Mayo Clinic study population was predominantly white, the recent study included a much more diverse cohort, allowing for new insights.

The data suggested that GNOD was a stronger predictor of pancreatic cancer in non-Hispanic white individuals, while the association was less pronounced in African American, Hispanic, and Asian American/Pacific Islander populations. This finding underscores the importance of studying diverse populations and tailoring early detection strategies accordingly. We are eager to determine whether the additional clinical parameters incorporated into EDI, via the ENDPAC score, help enrich the likelihood of finding pancreatic cancer amongst the participants across racial and ethnic groups.

Anna: In January 2025, PanCAN’s EDI study reached a milestone by fully enrolling more than 8,800 participants. Why is this significant?

 Reaching full enrollment is a critical milestone in research. The scale and diversity of the EDI cohort allows for rigorous, prospective analysis of the ENDPAC model and other related early detection signals. Unlike retrospective studies, which rely on existing data, prospective studies follow participants in real time, offering stronger evidence of cause and effect. This large, well-characterized group will enable researchers to examine, over the next several years, whether early indicators like high blood sugar and weight loss truly lead to earlier diagnosis and ultimately better outcomes.

Anna: What message would you share with PanCAN’s donors and supporters about the impact of their contributions on early detection research?

 Donor support is absolutely vital to making this research possible. Studies like GNOD and EDI are multi-year, resource-intensive efforts that wouldn’t happen without funding. The recent GNOD study has now validated the foundational hypothesis behind EDI, showing a real signal worth pursuing. The upcoming results from EDI will take that one step further. This work brings us closer to a future where high-risk individuals can be flagged through routine testing and potentially diagnosed early, transforming the pancreatic cancer landscape. Thanks to our supporters, we are making real progress toward that goal.

Anna: Thank you, Lynn, for sharing such insightful perspectives and helping us better understand the importance and promise of early detection in pancreatic cancer.

This conversation highlights the incredible progress being made. As we await the results of the EDI in the coming years, it’s clear that this study and the dedicated researchers behind it have laid crucial groundwork for the future of pancreatic cancer detection and care. PanCAN’s unwavering commitment to early detection is reshaping what’s possible in the fight against pancreatic cancer.
Every data point, every enrolled participant, and every donor contribution brings us closer to a future where pancreatic cancer is no longer primarily a late-stage diagnosis. Together, we’re building hope and a roadmap for earlier detection, more personalized care, and better outcomes for all patients.

Stay tuned for future updates as we continue to spotlight the science and stories propelling this mission forward.

Editor’s note: The “Research Spotlight” series is written by

, PanCAN’s Chief Scientific and Medical Officer. Each month, Dr. Berkenblit shares her insights into the latest news and research in pancreatic cancer. Follow Dr. Berkenblit on

Articles

Pancreatic cancer is often diagnosed at an advanced stage, limiting treatment options. PanCAN's Early Detection Initiative (EDI) aims to identify early indicators, such as elevated blood sugar, to improve early diagnosis and outcomes. The ENDPAC risk score, which considers age, blood sugar, and weight changes, is central to this effort. The EDI study achieved full enrollment of over 8,800 participants in January 2025, enabling prospective analysis. Recent findings highlight racial and ethnic differences in risk, emphasizing the need for diverse study populations and tailored detection strategies.

Pancreatic cancer remains one of the deadliest cancers because it is often detected at an advanced stage when treatment options are limited.

Research Spotlight by Dr. Anna Berkenblit: Q&A with Lynn Matrisian, PhD, MBA, Chief Science Advisor at PanCAN

Pancreatic cancer is one of the most challenging cancers to treat: © vitanovski - stock.adobe.com.

Pancreatic cancer is one of the most challenging cancers to treat, often requiring highly complex surgical procedures and advanced molecular insights to guide therapy. From groundbreaking surgical innovations to targeted genetic research, the landscape of pancreatic cancer treatment is shifting toward more personalized, and more hopeful approaches.

One such advancement is the robotic Whipple, a high-tech way to perform one of the most intricate operations in surgical oncology. Paired with an increasing understanding of genetic mutations like KRAS, which play a critical role in pancreatic cancer, these developments are transforming how patients are diagnosed, treated, and supported.

While these advancements are still emerging, they offer a powerful sense of progress and possibility. Access to robotic surgery and precision medicine may still be limited to certain centers and patient populations, but awareness and advocacy can help expand availability. Patients and caregivers equipped with the right information are empowered to ask critical questions, seek out specialists, and explore all available options, including clinical trials and biomarker testing—to make informed decisions about care.

 by PanCAN’s Chief Scientific and Medical Officer Anna Berkenblit, MD, MMSc, she explores the intersection of surgical innovation and molecular medicine, offering a glimpse into the promising future of pancreatic cancer care.

Pancreatic cancer treatment is evolving with advancements in surgical techniques and molecular insights, leading to more personalized approaches. The robotic Whipple procedure exemplifies surgical innovation, while understanding genetic mutations like KRAS enhances targeted therapies. Although these advancements are not yet universally accessible, they signify progress and potential in pancreatic cancer care. Increased awareness and advocacy are crucial for expanding access to these innovations. Patients and caregivers, informed about options such as clinical trials and biomarker testing, can make empowered decisions regarding their treatment and care.

Pancreatic cancer is one of the most challenging cancers to treat.

Advances in surgical techniques and targeted therapies for Pancreatic Cancer

This month’s Research Spotlight highlights significant advancements in pancreatic cancer research and patient support. © - stock.adobe.com

This month’s Research Spotlight highlights significant advancements in pancreatic cancer research and patient support. The National Comprehensive Cancer Network (NCCN) has released new patient-facing guidelines on genetic testing for hereditary cancers, including pancreatic cancer. These guidelines provide essential information on genetic risks, testing options, and early detection strategies, helping patients and their families make informed healthcare decisions. PanCAN strongly encourages genetic and tumor biomarker testing for all pancreatic cancer patients to guide personalized treatment and identify potential risks for family members.

PanCAN’s Early Detection Initiative (EDI) has successfully enrolled over 8,800 participants to study the link between new-onset diabetes and pancreatic cancer. The goal of this initiative is to develop a screening method for high-risk individuals that detects pancreatic cancer early when it is still surgically treatable. As data from the study continues to be analyzed over the coming years, researchers are hopeful that this initiative will lead to the implementation of a new screening strategy that improves early detection and patient outcomes.

Additionally, pancreatic cancer disproportionately affects Black Americans, who have higher incidence and mortality rates than other racial and ethnic groups. The American Cancer Society’s latest report attributes these disparities to structural racism and inequitable access to healthcare. Addressing these disparities requires continued advocacy and research funding. PanCAN leaders recently visited Capitol Hill to urge federal investment in pancreatic cancer research, emphasizing the importance of sustained funding for scientific progress and improved patient outcomes. PanCAN encourages supporters to engage in advocacy efforts to ensure that funding for life-saving research remains a national priority.

Read more from PanCAN’s Chief Scientific & Medical Officer Dr. Anna Berkenblit: 

https://pancan.org/news/research-spotlight-2/

Recent advancements in pancreatic cancer research emphasize the importance of genetic testing and early detection. The NCCN has introduced guidelines for hereditary cancer genetic testing, aiding patients in making informed decisions. PanCAN advocates for genetic and tumor biomarker testing to personalize treatment and assess familial risks. The Early Detection Initiative aims to link new-onset diabetes with pancreatic cancer for early screening. Disparities in pancreatic cancer incidence among Black Americans highlight the need for advocacy and research funding to address structural racism and healthcare access issues.

This month’s Research Spotlight highlights significant advancements in pancreatic cancer research and patient support. 

Insights into the Latest Trends in Pancreatic Cancer

A recent report was released revealing a sobering trend for pancreatic cancer.

The recent American Cancer Society’s Cancer Statistics, 2025 report was released revealing a sobering trend for pancreatic cancer. Despite increases over the past three years, the five-year relative survival rate for pancreatic cancer remains flat at 13%, and just 8% for people diagnosed with the most common form of pancreatic cancer, pancreatic adenocarcinoma. 

According to the American Cancer Society’s Cancer Statistics, 2025, report, an estimated 67,440 Americans are expected to be diagnosed with pancreatic cancer in 2025, and an estimated 51,980 are predicted to die from the disease this year.While overall cancer mortality is decreasing, the annual report highlights that pancreatic cancer remains the third-leading cause of cancer-related deaths in the United States. Evidence suggests that it is on track to become the second-leading cause in the coming years. The five-year relative survival for Black people with pancreatic cancer is lower at 11%, consistent with the disparities seen for cancer overall.

As one of the five most lethal cancers, pancreatic cancer, unlike lung, breast, prostate and colorectal cancer, is the only one that does not have a standard screening strategy. The lack of progress highlights the need for focused research efforts to narrow the gap between outcomes from pancreatic cancer and other major cancer types. 

There is good news. Overall, cancer mortality rates are decreasing. Although pancreatic cancer continues to lag behind, successes in other cancers can provide a roadmap and highlight focus areas that may have a positive impact on outcomes for patients with pancreatic cancer in the years to come.

“While we’ve seen incremental progress in the treatment of pancreatic cancer, it’s sobering to know that pancreatic cancer survival has not increased and remains the only major cancer with a five-year survival rate below 20%,” said Anna Berkenblit, M.D., MMSc, Chief Scientific and Medical Officer at PanCAN. “The minimal improvement in survival in recent years is in part related to more people being diagnosed with incidentally detected, well differentiated neuroendocrine tumors, which are less aggressive than pancreatic adenocarcinomas. This highlights the need for screening and surveillance strategies for pancreatic adenocarcinoma as well as the need for better therapies, which will require more research funding.”

The bad news is that there continues to be a lack of research funding for an early detection strategy and better treatments for patients.

Dr. Berkenblit added, “I am hopeful that with the approval of new drugs for the treatment of diabetes and obesity, both of which are risk factors for pancreatic cancer, and the development of targeted therapies like RAS inhibitors for pancreatic cancer, we will begin to see improved outcomes in the years ahead.” 

Learn more about how you can help by reading the article: 

A Call to Action: Progress for Pancreatic Cancer Depends on You.

Pancreatic cancer remains a significant challenge, with a stagnant five-year relative survival rate of 13%, and only 8% for pancreatic adenocarcinoma. The American Cancer Society's 2025 report estimates 67,440 new cases and 51,980 deaths in 2025, highlighting its status as the third-leading cause of cancer-related deaths in the U.S. Despite overall cancer mortality declining, pancreatic cancer lacks a standard screening strategy, underscoring the need for focused research. Promising developments in diabetes and obesity treatments, and targeted therapies like RAS inhibitors, offer hope for future improvements.

The recent American Cancer Society’s Cancer Statistics, 2025 report was released revealing a sobering trend for pancreatic cancer.

Pancreatic Cancer Action Network

Research Spotlight by Dr. Anna Berkenblit: Q&A with Lynn Matrisian, PhD, MBA, Chief Science Advisor at PanCAN

Advances in surgical techniques and targeted therapies for Pancreatic Cancer

Insights into the Latest Trends in Pancreatic Cancer

Pancreatic Cancer Diagnoses and Mortality Rates Rise

Latest News